{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Anemia, Increase (Inc) G1-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Anemia, Inc G2-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Anemia, Inc G3-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Hemoglobin increased, Inc G1-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Hemoglobin increased, Inc G2-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"Hemoglobin increased, Inc G3-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Lymphocyte count decreased, Inc G1-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Lymphocyte count decreased, Inc G2-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Lymphocyte count decreased, Inc G3-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Lymphocyte count increased, Inc G1-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Lymphocyte count increased, Inc G2-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Lymphocyte count increased, Inc G3-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Neutrophil count decreased, Inc G1-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Neutrophil count decreased, Inc G2-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Neutrophil count decreased, Inc G3-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"title":"Platelet count decreased, Inc G1-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"title":"Platelet count decreased, Inc G2-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"90"}],"units":"Participants"}],"title":"Platelet count decreased, Inc G3-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Eosi, Inc G1-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"title":"WBC decreased, Inc G1-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"title":"WBC decreased, Inc G2-G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"95"}],"units":"Participants"}],"title":"WBC decreased, Inc G3-G4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"102"}],"units":"Participants"}],"description":"Blood samples were collected for evaluation of hematology parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \\[White Blood Cells (WBC)\\]","groups":[{"description":"Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle","id":"OG000","title":"Belantamab Mafodotin"},{"description":"Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \\>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)","id":"OG001","title":"Pomalidomide Plus Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories. Participants were counted more than once within some categories, hence the percentages may not add up to 100%.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and up to approximately 263 weeks","title":"Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Hematology","type":"SECONDARY","unitOfMeasure":"Participants"}